1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Leafly Holdings, Inc.

Leafly Holdings, Inc.

LFLYW
Leafly Holdings, Inc.US flagNASDAQ Global Market
0.00
USD
-0.01
- -
299,934.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
30
- -
43
47
42
35
33
Operating Margin (%)
-106.39
- -
-24.69
-59.13
-16.69
-9.05
-7.85
Depreciation Expense
- -
- -
- -
- -
1
1
2
Net Income, GAAP
-32
-2
-12
5
-9
-6
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-106.2
- -
-27.94
10.7
-22.48
-16.59
-15.36
Working Capital
- -
- -
-9
20
14
-18
-19
LT Debt
7
- -
- -
29
29
- -
- -
Total Equity
-5
127
-9
-6
-12
-15
-17
Return on Invested Capital (%)
- -
- -
- -
-131.77
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-21.24
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
30
29
26
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
17
17
11
Cash, Cash Equivalents & STI
14
15
9
Accounts Receivable, Net
2
2
1
Inventories
- -
- -
- -
Total Current Liabilities
34
35
31
Payables & Accruals
1
2
2
ST Debt
30
29
26
Deferred Revenue
2
2
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-512.39%
21.28%
Free Cash Flow
- -
220.53%
-98.59%
Net Income, GAAP
- -
-4.31%
-39.49%
Sales/Revenue/Turnover
- -
- -
-18.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
11
11
11
10
42
2024
9
9
8
9
35
2025
8
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Yoko Miyashita
Full Time Employees
204
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
600 1st Ave Seattle WA United States of America 98104
IPO Date
Feb 7, 2022
CIK
0001785592
Website
leafly.com
Similar Companies
Ligand Pharmaceuticals Incorporated (LGNYZ)
Pharmaron Beijing Co., Ltd. (3759.HK)
Zenith Drugs Ltd. (ZENITHDRUG.NS)
Neighbourly Pharmacy Inc. (NBLY.TO)
Hanshang Group Co., Ltd. (600774.SS)
Damora Therapeutics, Inc. (GLTO)
Business
Leafly Holdings, Inc. (LFLYW) operates as a leading online cannabis discovery marketplace and information resource, connecting consumers with licensed retailers and brands through its platform. The company offers detailed cannabis strain information, including over 5,000 strains with user reviews and effects; retailer locators with menus, hours, and contact details; online ordering and delivery options for pickup where legally available; digital advertising solutions such as banner ads, sponsored listings, branded content, and email campaigns; subscription-based marketplace listings and add-on activations for brands; and data analytics tools providing market insights, consumer behavior trends, and business intelligence for cannabis businesses. Leafly serves consumers, over 7,800 brands, and more than 4,600 retailers primarily in the United States, with international reach, generating revenue through its Retail and Brands segments. Founded in 2010 and headquartered in Seattle, Washington, the company attracts over 100 million annual visitors to its website and mobile applications. In recent developments, Leafly reported third quarter 2024 financial results in November 2024, with revenue of $8.4 million, a net loss of $1.1 million, positive adjusted EBITDA of $0.4 million for the second consecutive quarter, and stabilized retail revenue amid cost reductions; transitioned to over-the-counter trading following Nasdaq delisting due to non-compliance with listing standards; extended the maturity of its 2022 convertible notes to July 2025 with principal reductions; converted portions of debt to equity; and named Super Boof as its Strain of the Year 2024.